These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 11025617)

  • 1. Disappearance of FVIII inhibitors in a severe hemophilia A neonate after steroid treatment correlated with a cytokine shift toward a T-helper 2 pattern.
    Vianello F; Zanon E; Zerbinati P; Innella B; Girolami A
    Haematologica; 2000 Oct; 85(10):1114-5. PubMed ID: 11025617
    [No Abstract]   [Full Text] [Related]  

  • 2. Blockade of CD40/CD40 ligand interactions prevents induction of factor VIII inhibitors in hemophilic mice but does not induce lasting immune tolerance.
    Reipert BM; Sasgary M; Ahmad RU; Auer W; Turecek PL; Schwarz HP
    Thromb Haemost; 2001 Dec; 86(6):1345-52. PubMed ID: 11776297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokine production by CD4+ T cells specific for coagulation factor VIII in healthy subjects and haemophilia A patients.
    Hu G; Guo D; Key NS; Conti-Fine BM
    Thromb Haemost; 2007 May; 97(5):788-94. PubMed ID: 17479189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of factor VIII inhibitors in patients with hemophilia A in Brazil.
    Rieger A; Roisenberg I
    Thromb Haemost; 1999 Mar; 81(3):475-6. PubMed ID: 10102489
    [No Abstract]   [Full Text] [Related]  

  • 5. Distribution of Th1- and Th2-induced anti-factor VIII IgG subclasses in congenital and acquired hemophilia patients.
    Reding MT; Lei S; Lei H; Green D; Gill J; Conti-Fine BM
    Thromb Haemost; 2002 Oct; 88(4):568-75. PubMed ID: 12362225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of the immune response to human factor VIII in murine hemophilia A.
    Wu H; Reding M; Qian J; Okita DK; Parker E; Lollar P; Hoyer LW; Conti-Fine BM
    Thromb Haemost; 2001 Jan; 85(1):125-33. PubMed ID: 11204564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endocytic receptor for pro-coagulant factor VIII: relevance to inhibitor formation.
    Navarrete AM; Dasgupta S; Teyssandier M; Repesse Y; Delignat S; André S; Bayry J; Kaveri SV; Lacroix-Desmazes S
    Thromb Haemost; 2010 Dec; 104(6):1093-8. PubMed ID: 20886186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Poly-electrolyte fractionated porcine factor VIII in the treatment of hemophilia A].
    Ferencz T; Skopál J; Csáki C; Laczkó M; Schuler D; Borsi J
    Orv Hetil; 1993 Dec; 134(52):2873-5. PubMed ID: 8272354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolerance to factor VIII inhibitors in hemophilia A patients: a French twist.
    Pascual V; Capra JD
    J Clin Invest; 1996 Mar; 97(6):1357-8. PubMed ID: 8617864
    [No Abstract]   [Full Text] [Related]  

  • 10. Single cell analysis of factor VIII-specific T cells in hemophilic mice after treatment with human factor VIII.
    Sasgary M; Ahmad RU; Schwarz HP; Turecek PL; Reipert BM
    Thromb Haemost; 2002 Feb; 87(2):266-72. PubMed ID: 11858486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are low-density lipoprotein receptor-related protein 1 or non-neutralizing antibodies predictors of FVIII in vivo recovery in haemophilia A patients?
    Clere AS; Diaz I; Lebreton A; Lavigne-Lissalde G; Schved JF; Biron-Andreani C
    Haemophilia; 2014 Nov; 20(6):e406-8. PubMed ID: 25311419
    [No Abstract]   [Full Text] [Related]  

  • 12. Immune tolerance in hemophilia with factor VIII inhibitors: predictors of success.
    Mariani G; Kroner B;
    Haematologica; 2001 Nov; 86(11):1186-93. PubMed ID: 11694405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunobiology of inhibitor development in hemophilia A.
    Fijnvandraat K; Bril WS; Voorberg J
    Semin Thromb Hemost; 2003 Feb; 29(1):61-8. PubMed ID: 12640567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is a change of factor VIII product a risk factor for the development of a factor VIII inhibitor?
    Yee TT; Lee CA
    Thromb Haemost; 1999 May; 81(5):852. PubMed ID: 10365768
    [No Abstract]   [Full Text] [Related]  

  • 15. New protocol for immune tolerance induction in acquired hemophilia.
    Nemes L; Pitlik E
    Haematologica; 2000 Oct; 85(10 Suppl):64-8. PubMed ID: 11187874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitor development in a multitransfused patient with severe haemophilia A.
    van den Berg HM; Roosendaal G; Voorberg J; Mauser-Bunschoten EP
    Thromb Haemost; 1999 Jul; 82(1):151-2. PubMed ID: 10456472
    [No Abstract]   [Full Text] [Related]  

  • 17. Long-term persistence of anti-factor VIII antibody-secreting cells in hemophilic mice after treatment with human factor VIII.
    Hausl C; Maier E; Schwarz HP; Ahmad RU; Turecek PL; Dorner F; Reipert BM
    Thromb Haemost; 2002 May; 87(5):840-5. PubMed ID: 12038787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allergenic vaccines administration and inhibitor development in haemophilia.
    Bermejo N; Martín Aguilera C; Carnicero F; Bergua J
    Haemophilia; 2012 Sep; 18(5):e392-3. PubMed ID: 22672147
    [No Abstract]   [Full Text] [Related]  

  • 19. Characterization of antibodies to factor VIII in hemophilia A patients treated by immune tolerance therapy.
    Scandella D; Reyes H; Felch M; Sakurai Y
    Haematologica; 2000 Oct; 85(10 Suppl):86-8. PubMed ID: 11187882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factor VIII inhibitor with catalytic activity towards factor VIII.
    Lacroix-Desmazes S; Sooryanarayana ; Moreau A; Kazatchkine MD; Kaveri SV
    Haematologica; 2000 Oct; 85(10 Suppl):89-92. PubMed ID: 11187883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.